Abstract: It is an object of the present invention to provide a transgenic non-human animal, which can appropriately evaluate properties, pharmacological effects and safety of a molecular targeted substance or targeted drug to a human specific molecule, and to provide a method for producing the transgenic non-human animal, which comprises a gene encoding a human specific molecule and a gene encoding a human Fc? receptor family, both genes being introduced in the animal, thereby expressing the gene encoding a human specific molecule and the gene encoding a human Fc? receptor family.

Abstract: It is an object of the present invention to provide a monoclonal antibody, which is suitable for the quantitative analysis of asparagine synthetase in a cell. The present invention provides a monoclonal antibody which specifically recognizes asparagine synthetase that is present in a cell.

Abstract: A pharmaceutical agent for improvement in pruritus cutaneus associated with renal failure and/or for the treatment of renal failure and/or its complications containing as an effective ingredient oligosaccharide or oligosaccharides such as, but not limited to fructo-oligosaccharide, galacto-oligosaccharide, isomalto-oligosaccharide, malto-oligosaccharide, lacto-sucrose and/or xylo-oligosaccharide, in particular, lactulose, rhamnose and lactitol.

Abstract: A polypetide vaccine is disclosed with the amino acid sequence of Asp-Pro-Arg-Val-Arg-Gly-Leu-Try-Phe-Pro-Ala-Gly-Gly-Ser-Ser-Ser-Gly-Thr-Va l that bears the receptor for polymerized human serum albumin capable of raising antibodies to inhibit the access and entry of hepatitis B virus (HBV) to hepatocytes. The polypeptide vaccine is also shown in which the 9th amino acid residue (Phe) is replaced by leucine. In addition, there is disclosed hepatitis B polypeptide vaccine P31 which is capable of raising antibodies to block the attachment of HBV to hepatocytes.